{
    "organizations": [],
    "uuid": "91b299e485fb02b457466a956a01e740b590be84",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-spark-therapeutics-reports-cash-an/brief-spark-therapeutics-reports-cash-and-cash-equivalents-and-marketable-securities-of-540-2-mln-as-of-dec-31-2017-idUSASB0C6DD",
    "ord_in_thread": 0,
    "title": "BRIEF-Spark Therapeutics Reports Cash And Cash Equivalents And Marketable Securities Of $540.2 Mln As Of Dec. 31, 2017",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 20 (Reuters) - Spark Therapeutics Inc:\n* SPARK THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND RECENT BUSINESS PROGRESS\n* SPARK THERAPEUTICS INC - AS OF DEC. 31, 2017, SPARK HAD CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $540.2 MILLION Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)\n ",
    "published": "2018-02-20T20:58:00.000+02:00",
    "crawled": "2018-02-21T21:40:20.037+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "spark",
        "therapeutic",
        "inc",
        "spark",
        "therapeutic",
        "report",
        "financial",
        "result",
        "recent",
        "business",
        "progress",
        "spark",
        "therapeutic",
        "inc",
        "spark",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}